sctil
Cell therapyexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 18, 2022 (NCT05342506)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05730361 | Phase 1 | Feb 28, 2023 | Government of China, Peking University |
| NCT05499715 | Phase 1 | Sep 30, 2022 | Beijing ChineoMedical Technology Co., Ltd, Chinese Academy of Medical Sciences |
| NCT05342506 | Phase 2 | Apr 18, 2022 | Chinese Academy of Medical Sciences |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 2 | 2 | 2022 |
| Beijing ChineoMedical Technology Co., Ltd | For profit | 1 | 0 | 1 | 2022 |
| Government of China | Government | 1 | 0 | 1 | 2023 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2023 |
4 organizations
Page 1 / 1